European seroepidemiology network 2: Standardisation of assays for seroepidemiology of varicella zoster virus.

2.50
Hdl Handle:
http://hdl.handle.net/10029/5603
Title:
European seroepidemiology network 2: Standardisation of assays for seroepidemiology of varicella zoster virus.
Authors:
Ory, Fernando de; Echevarría, José Manuel; Kafatos, George; Anastassopoulou, Cleo; Andrews, Nick; Backhouse, Josephine; Berbers, Guy A M; Bruckova, Blazena; Cohen, Daniel I; Melker, Hester E de; Davidkin, Irja; Gabutti, Giovanni; Hesketh, Louise M; Johansen, Kari; Jokinen, Sari; Jones, Lindsay; Linde, Anika; Miller, Elisabeth; Mossong, Joël; Nardone, Anthony; Rota, Maria Cristina; Sauerbrei, Andreas; Schneider, François; Smetana, Zahava; Tischer, Annedore; Tsakris, Athanassios; Vranckx, Robert
Abstract:
BACKGROUND: The aim of the European Sero-Epidemiology Network (ESEN2) is to harmonise the serological surveillance of vaccine-preventable diseases in Europe. OBJECTIVE: To allow comparison of antibody prevalence in different countries by standardising results into common units. STUDY DESIGN: For varicella zoster virus (VZV), a reference laboratory established a panel of 148 samples, characterised by indirect enzyme-immunoassay (ELISA), indirect immunofluorescence, and complement fixation test. Fifty-seven samples were also studied by the fluorescence antibody to membrane antigen test. The geometric mean of the antibody activity (GMAA) obtained from four ELISA determinations was used to characterise each sample of the panel as positive (GMAA: >100 mIU/ml), equivocal (GMAA: 50-100 mIU/ml) or negative (GMAA: <50 mIU/ml) for antibody to VZV (anti-VZV). Thirteen laboratories, using five different ELISA tests, tested the panel. RESULTS: Agreement with the reference laboratory was above 85% in all cases, and the R(2) values obtained from regression analysis of the quantitative results were always higher than 0.87. Finally, the regression equations could be used to convert national values into a common unitage. CONCLUSION: This study confirmed that results for anti-VZV obtained by different ELISA methods can be converted into common units, enabling the comparison of the seroprevalence profiles obtained in the participant countries.
Citation:
J. Clin. Virol. 2006, 36(2):111-8
Issue Date:
1-Jun-2006
URI:
http://hdl.handle.net/10029/5603
DOI:
10.1016/j.jcv.2006.01.017
PubMed ID:
16616612
Type:
Article
Language:
en
ISSN:
1386-6532
Appears in Collections:
Infectious Diseases

Full metadata record

DC FieldValue Language
dc.contributor.authorOry, Fernando de-
dc.contributor.authorEchevarría, José Manuel-
dc.contributor.authorKafatos, George-
dc.contributor.authorAnastassopoulou, Cleo-
dc.contributor.authorAndrews, Nick-
dc.contributor.authorBackhouse, Josephine-
dc.contributor.authorBerbers, Guy A M-
dc.contributor.authorBruckova, Blazena-
dc.contributor.authorCohen, Daniel I-
dc.contributor.authorMelker, Hester E de-
dc.contributor.authorDavidkin, Irja-
dc.contributor.authorGabutti, Giovanni-
dc.contributor.authorHesketh, Louise M-
dc.contributor.authorJohansen, Kari-
dc.contributor.authorJokinen, Sari-
dc.contributor.authorJones, Lindsay-
dc.contributor.authorLinde, Anika-
dc.contributor.authorMiller, Elisabeth-
dc.contributor.authorMossong, Joël-
dc.contributor.authorNardone, Anthony-
dc.contributor.authorRota, Maria Cristina-
dc.contributor.authorSauerbrei, Andreas-
dc.contributor.authorSchneider, François-
dc.contributor.authorSmetana, Zahava-
dc.contributor.authorTischer, Annedore-
dc.contributor.authorTsakris, Athanassios-
dc.contributor.authorVranckx, Robert-
dc.date.accessioned2006-10-26T10:48:40Z-
dc.date.available2006-10-26T10:48:40Z-
dc.date.issued2006-06-01-
dc.identifier.citationJ. Clin. Virol. 2006, 36(2):111-8en
dc.identifier.issn1386-6532-
dc.identifier.pmid16616612-
dc.identifier.doi10.1016/j.jcv.2006.01.017-
dc.identifier.urihttp://hdl.handle.net/10029/5603-
dc.description.abstractBACKGROUND: The aim of the European Sero-Epidemiology Network (ESEN2) is to harmonise the serological surveillance of vaccine-preventable diseases in Europe. OBJECTIVE: To allow comparison of antibody prevalence in different countries by standardising results into common units. STUDY DESIGN: For varicella zoster virus (VZV), a reference laboratory established a panel of 148 samples, characterised by indirect enzyme-immunoassay (ELISA), indirect immunofluorescence, and complement fixation test. Fifty-seven samples were also studied by the fluorescence antibody to membrane antigen test. The geometric mean of the antibody activity (GMAA) obtained from four ELISA determinations was used to characterise each sample of the panel as positive (GMAA: >100 mIU/ml), equivocal (GMAA: 50-100 mIU/ml) or negative (GMAA: <50 mIU/ml) for antibody to VZV (anti-VZV). Thirteen laboratories, using five different ELISA tests, tested the panel. RESULTS: Agreement with the reference laboratory was above 85% in all cases, and the R(2) values obtained from regression analysis of the quantitative results were always higher than 0.87. Finally, the regression equations could be used to convert national values into a common unitage. CONCLUSION: This study confirmed that results for anti-VZV obtained by different ELISA methods can be converted into common units, enabling the comparison of the seroprevalence profiles obtained in the participant countries.en
dc.format.extent315572 bytes-
dc.format.mimetypeapplication/pdf-
dc.language.isoenen
dc.titleEuropean seroepidemiology network 2: Standardisation of assays for seroepidemiology of varicella zoster virus.en
dc.typeArticleen
dc.format.digYES-

Related articles on PubMed

All Items in WARP are protected by copyright, with all rights reserved, unless otherwise indicated.